Aging Beautifully Part 3: Dementia
Upcoming SlideShare
Loading in...5

Aging Beautifully Part 3: Dementia






Total Views
Views on SlideShare
Embed Views



1 Embed 41 41


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • Today I will discuss Urinary Incontinence, the 2nd part of the Aging beautifully series.
  • Reversible cause of mental status change: alcohol abuse, thyroid dysfunction, dehydration and electrolyte disturbance, infection, vit b12 deficiency, medications: anticholinergics (for overactive bladder, tiotropium for asthma
  • IADLS (laundry, housekeeping, managing meds, may get lost in familiar places)
  • AP can enhancetherapietic
  • AP can enhancetherapietic
  • AP can enhancetherapietic
  • AP can enhancetherapietic
  • Pharmacists, we have a role to play… As patient advocates and front-line health care professionals we can educate, recommend better treatment alternatives, ensure their safety, and listen… so someday, our patients can say…

Aging Beautifully Part 3: Dementia Aging Beautifully Part 3: Dementia Presentation Transcript

  • You have 9 seconds left…Let’s Play!
  • Which color is missing??
  • Guess who’s who?Let’s Play!
  • Impressive!Scoreboard:• Dr. A• Dr. G• Dr. S• Dr. T
  • By the way,what istoday’s date?
  • Memory ispowerful.but not untilwe lose it thatwe fully realizeits significance
  • AgingBeautifully:Visions & RealitiesPart III: Dementia Christine HortillosaPharm.D. 2013 CandidateUniversity of Texas at Austin College of Pharmacy5. 9. 2013
  • DeliriumDementiaAcuteTwo of the following:•Misinterpretation, illusions, hallucinations•Incoherent speech•Disturbance in sleep-wake cycle•Change in psychomotor activityRelated to medical illness + medicationsReversibleProgressiveMarked by memory impairmentNot a normal part of agingIrreversible
  • Most common formof dementia is…Alzheimer’sdisease
  • mildmoderatesevere20-24Short-term memory loss;word-finding problemsLoss of IADLs10-19Disorientation to time, place,inability to engage in activitiesNeeds assistance with ADLs<10Loss of speech andambulation, incontinence of boweland bladderDependency in basic ADLs; often requiresaround-the-clock care*ADLS= activities of daily living (bathing, dressing); IADLS=instrumental activities of daily living (housekeeping); MMSE=Mini-Mental Status ExaminationMMSE Examples of cognitive lossExamples of functional lossStages
  • Drugs for Treatmentof Alzheimer’sDonepezilRivastigmineGalantamineMemantine
  • DonepezilStarting Dose 5 mg/day; No dose change for renalimpairmentMaintenance Dose 10mg/dayMay also increase to 23mg/dayProperties Cholinesterase inh; partly metabolizedby CYP 2D6 and 3A4Indication For all stages of Alzheimer’sAdverse Effects Bradycardia, syncope, weight loss,N/V/D, InsomniaDDI Anticholinergics, Antipsychotics, Beta-blockers, AlcoholAdministration At bedtime without regard to food
  • Starting Dose 1.5mg BID; No dosage change forrenal impairmentMaintenance Dose 3-6mg BIDProperties Cholinesterase inhIndication For mild to moderate Alzheimer’s andmild-to moderate dementia withParkinson’sAdverse Effects Has most intense cholinergic (N/V/D)ADE, bradycardia, syncope, dizziness,EPSDDI Anticholinergics, Antipsychotics, Beta-blockers, AlcoholAdministration With meals; for patch (avoid applicationto same spot for 14 days)Rivastigmine
  • Starting Dose 4 mg BID; Use not reco’d for CrCl<9ml/minMaintenance Dose 8-12mg BID or 8-24mg ER QdayProperties Cholinesterase inh and nicotinereceptor modulator; partly metabolizedby CYP 2D6 and 3A4Indication For mild-to-moderate Alzheimer’sAdverse Effects Bradycardia, syncope, weight loss,N/V/DDDI Anticholinergics, Antipsychotics, Beta-blockers, AlcoholAdministration With meals; if therapy is interrupted for3+ days, restart at lower dose andincrease to current doseGalantamine
  • MemantineStarting Dose 5 mg/day (max dose of 20mg for CrCl30-49 and max dose 5mg for CrCl 5-29)Maintenance Dose 10mg BIDProperties Blocks glutamate transmissionIndication For moderate to severe Alzheimers;may be used in combination withdonepezilAdverse Effects Hypertension, confusionDDI Sodium bicarbonate, TrimethoprimAdministration Without regard to food
  • Start with cholinesterase inhibitorsCaution: statistically significant difference ≠ clinical meaningful improvement
  • How long shouldthe therapy be?• Evaluation at 3-6 months for prevention ofdecline or improvement• Conflicting evidence in unresponsive patients• Taper upon discontinuation
  • arecritical ineffectivealzheimer’sdiseasemanagement.
  • With your help,I can preservemy memories alittle bit longer.
  • Discussion.